ArticleGynecologic oncology2017

Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.

Gulden Menderes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.